Geovax Labs, INC 8-K filings

GeoVax Labs has successfully completed a registered direct offering, raising approximately $4.6 million to support working capital and general corporate activities.

GeoVax Labs has successfully raised approximately $8.5 million through a registered direct offering of common stock and warrants, priced above the market.

GeoVax Labs announced a significant BARDA contract exceeding $350 million to advance its COVID-19 vaccine candidate, GEO-CM04S1, into a large Phase 2b clinical trial, alongside progress in its Gedeptin cancer therapy program.

GeoVax Labs has entered into a securities purchase agreement for a registered direct offering, expected to generate approximately $3.1 million in gross proceeds.

GeoVax Labs has resolved a Nasdaq listing deficiency by amending warrants issued in a recent private placement, ensuring continued compliance with shareholder approval rules.

GeoVax has received a significant award from BARDA to advance its next-generation COVID-19 vaccine candidate, GEO-CM04S1, into a Phase 2b clinical trial.

GeoVax Labs has received a notice from Nasdaq stating it no longer meets the minimum stockholders' equity requirement for continued listing.

GeoVax Labs held its annual meeting, approving a bylaws amendment to reduce quorum requirements and electing its slate of directors.

GeoVax Labs has entered into a securities purchase agreement for a registered direct offering, expected to raise approximately $1.3 million.

GeoVax Labs announced its first quarter 2024 financial results, along with updates on clinical trial progress, manufacturing advancements, and intellectual property developments.

GeoVax Labs announced its 2023 year-end financial results and provided an update on its clinical programs, including progress in COVID-19 and cancer vaccine development.

GeoVax Labs has successfully regained compliance with Nasdaq's minimum bid price requirement, avoiding delisting after a reverse stock split.

GeoVax Labs has executed a 1-for-15 reverse stock split, reducing its authorized common stock shares from 600 million to 150 million.

GeoVax Labs Inc. shareholders approved a reduction in authorized shares and a reverse stock split at a special meeting held on January 16, 2024.